Literature DB >> 19660509

Human leukocyte antigen-G is expressed in advanced-stage ovarian carcinoma of high-grade histology.

Catherine Menier1, Sophie Prevot, Edgardo D Carosella, Nathalie Rouas-Freiss.   

Abstract

HLA-G is a nonclassical MHC class I molecule with restricted normal tissue distribution, but whose expression is induced in pathologic situations such as cancer. In regard to the its immunosuppressive properties, it has been suggested that HLA-G could be a way for tumors to escape immunosurveillance. HLA-G has been described in almost all types of cancer, whatever their origins. Ovarian cancer is the second leading cause of death among women with gynecologic cancers, after breast cancer. The high mortality rate of this pathology is linked to its late discovery resulting from discreet symptomatology at early stages and the current paucity of highly sensitive and specific biomarkers. The aim of the present study was to analyze, in a French, retrospectively based study, whether HLA-G could be a marker for the detection of ovarian cancer and the prediction of clinical evolution. For this purpose, we looked for HLA-G expression in ovarian carcinoma lesions from low to high grade and stage, and we showed that HLA-G is selectively expressed in advanced-stage disease of high-grade histology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660509     DOI: 10.1016/j.humimm.2009.07.021

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  15 in total

Review 1.  HLA-G regulators in cancer medicine: an outline of key requirements.

Authors:  Ines Zidi; Nidhal Ben Amor
Journal:  Tumour Biol       Date:  2011-07-27

Review 2.  Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?

Authors:  Laurence Amiot; Soldano Ferrone; Hans Grosse-Wilde; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2010-11-10       Impact factor: 9.261

Review 3.  Use of allogeneic NK cells for cancer immunotherapy.

Authors:  Melissa A Geller; Jeffrey S Miller
Journal:  Immunotherapy       Date:  2011-12       Impact factor: 4.196

4.  The frequency of CD25+CD4+ and FOXP3+ regulatory T cells in ectopic endometrium and ectopic decidua.

Authors:  Pawel Basta; Marcin Majka; Wojciech Jozwicki; Ewelina Lukaszewska; Anna Knafel; Marek Grabiec; Elzbieta Stasienko; Lukasz Wicherek
Journal:  Reprod Biol Endocrinol       Date:  2010-10-05       Impact factor: 5.211

5.  Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Mol Med       Date:  2015-08-24       Impact factor: 6.354

Review 6.  The role of HLA-G in immunity and hematopoiesis.

Authors:  Edgardo D Carosella; Silvia Gregori; Nathalie Rouas-Freiss; Joel LeMaoult; Catherine Menier; Benoit Favier
Journal:  Cell Mol Life Sci       Date:  2010-11-30       Impact factor: 9.261

7.  Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

Authors:  Emilia Andersson; Lisa Villabona; Kjell Bergfeldt; Joseph W Carlson; Soldano Ferrone; Rolf Kiessling; Barbara Seliger; Giuseppe V Masucci
Journal:  Cancer Immunol Immunother       Date:  2012-01-19       Impact factor: 6.968

Review 8.  Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association.

Authors:  Eduardo A Donadi; Erick C Castelli; Antonio Arnaiz-Villena; Michel Roger; Diego Rey; Philippe Moreau
Journal:  Cell Mol Life Sci       Date:  2010-11-24       Impact factor: 9.261

9.  HLA-G UTR haplotype conservation in the Malian population: association with soluble HLA-G.

Authors:  Federico Carlini; Karim Traore; Nissem Cherouat; Pierre Roubertoux; Stéphane Buhler; Martì Cortey; Sophie Simon; Ogobara Doumbo; Jacques Chiaroni; Christophe Picard; Julie Di Cristofaro
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

Review 10.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.